Literature DB >> 33059370

Penetrating the brain tumor space with DNA damage response inhibitors.

Ranjit S Bindra1.   

Abstract

Entities:  

Keywords:  DNA repair; GBM; PARP inhibitors; Phase 0; pharmacodynamics; pharmacokinetics

Year:  2020        PMID： 33059370      PMCID： PMC7746934          DOI： 10.1093/neuonc/noaa228

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN： 1522-8517            Impact factor:   12.300


× No keyword cloud information.
  14 in total

Review 1.  Poly(ADP-ribose) polymerase inhibition: past, present and future.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Nat Rev Drug Discov       Date:  2020-09-03       Impact factor: 84.694

2.  Evaluation of Pharmacodynamic Responses to Cancer Therapeutic Agents Using DNA Damage Markers.

Authors:  Deborah F Wilsker; Allison M Barrett; Angie B Dull; Scott M Lawrence; Melinda G Hollingshead; Alice Chen; Shivaani Kummar; Ralph E Parchment; James H Doroshow; Robert J Kinders
Journal:  Clin Cancer Res       Date:  2019-02-21       Impact factor: 12.531

3.  Baseline requirements for novel agents being considered for phase II/III brain cancer efficacy trials: conclusions from the Adult Brain Tumor Consortium's first workshop on CNS drug delivery.

Authors:  Stuart A Grossman; Carlos G Romo; Michelle A Rudek; Jeffrey Supko; Joy Fisher; L Burt Nabors; Patrick Y Wen; David M Peereboom; Benjamin M Ellingson; William Elmquist; Fred G Barker; David Kamson; Jann N Sarkaria; William Timmer; Ranjit S Bindra; Xiaobu Ye
Journal:  Neuro Oncol       Date:  2020-10-14       Impact factor: 12.300

4.  Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase.

Authors:  Helen E Bryant; Niklas Schultz; Huw D Thomas; Kayan M Parker; Dan Flower; Elena Lopez; Suzanne Kyle; Mark Meuth; Nicola J Curtin; Thomas Helleday
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

5.  PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status.

Authors:  Ben Fulton; Susan C Short; Allan James; Stefan Nowicki; Catherine McBain; Sarah Jefferies; Caroline Kelly; Jon Stobo; Anna Morris; Aoife Williamson; Anthony J Chalmers
Journal:  Clin Transl Radiat Oncol       Date:  2017-11-21

6.  PARP Inhibitors for Sensitization of Alkylation Chemotherapy in Glioblastoma: Impact of Blood-Brain Barrier and Molecular Heterogeneity.

Authors:  Shiv K Gupta; Emily J Smith; Ann C Mladek; Shulan Tian; Paul A Decker; Sani H Kizilbash; Gaspar J Kitange; Jann N Sarkaria
Journal:  Front Oncol       Date:  2019-01-22       Impact factor: 6.244

7.  Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial.

Authors:  Catherine Hanna; Kathreena M Kurian; Karin Williams; Colin Watts; Alan Jackson; Ross Carruthers; Karen Strathdee; Garth Cruickshank; Laurence Dunn; Sara Erridge; Lisa Godfrey; Sarah Jefferies; Catherine McBain; Rebecca Sleigh; Alex McCormick; Marc Pittman; Sarah Halford; Anthony J Chalmers
Journal:  Neuro Oncol       Date:  2020-12-18       Impact factor: 12.300

8.  Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.

Authors:  Hannah Farmer; Nuala McCabe; Christopher J Lord; Andrew N J Tutt; Damian A Johnson; Tobias B Richardson; Manuela Santarosa; Krystyna J Dillon; Ian Hickson; Charlotte Knights; Niall M B Martin; Stephen P Jackson; Graeme C M Smith; Alan Ashworth
Journal:  Nature       Date:  2005-04-14       Impact factor: 69.504

Review 9.  Gray Areas in the Gray Matter: IDH1/2 Mutations in Glioma.

Authors:  Martin J van den Bent; Ingo K Mellinghoff; Ranjit S Bindra
Journal:  Am Soc Clin Oncol Educ Book       Date:  2020-03

10.  Pamiparib is a potent and selective PARP inhibitor with unique potential for the treatment of brain tumor.

Authors:  Yao Xiong; Yin Guo; Ye Liu; Hexiang Wang; Wenfeng Gong; Yong Liu; Xing Wang; Yajuan Gao; Fenglong Yu; Dan Su; Fan Wang; Yutong Zhu; Yuan Zhao; Yiyuan Wu; Zhen Qin; Xuebing Sun; Bo Ren; Bin Jiang; Wei Jin; Zhirong Shen; Zhiyu Tang; Xiaomin Song; Lai Wang; Xuesong Liu; Changyou Zhou; Beibei Jiang
Journal:  Neoplasia       Date:  2020-07-08       Impact factor: 5.715
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.